A Comparison of Two DAAs Used in a Unique Model of Care to Treat Hepatitis C Infections in New Jersey.

IF 3.8 4区医学 Q2 IMMUNOLOGY

Open Forum Infectious Diseases Pub Date : 2024-11-27 eCollection Date: 2024-12-01 DOI:10.1093/ofid/ofae645

Jihad Slim, Paul Bellafiore, Barbara Tempalski, Corey Rosmarin-DeStefano, Kevin Leyden, Juan Torres, Sheena Duprey, Emily Levaggi

引用次数: 0

Abstract

In this prospective observational study, we compare the efficacy of glecaprevir/pibrentasvir vs sofosbuvir/velpatasvir in treating hepatitis C within a unique model of care utilizing a combination of telehealth, an ambulatory van, case management, and a contracted pharmacy. Among 769 patients treated, 90.4% completed treatment, with 9.6% lost to follow-up. Both regimens demonstrated high completion rates and efficacy.

查看原文本刊更多论文

比较新泽西州在治疗丙型肝炎感染的独特护理模式中使用的两种 DAAs。

在这项前瞻性观察研究中，我们比较了 glecaprevir/pibrentasvir 与 sofosbuvir/velpatasvir 在治疗丙型肝炎方面的疗效，这种独特的治疗模式综合利用了远程医疗、流动车、个案管理和签约药房。在接受治疗的 769 名患者中，90.4% 的患者完成了治疗，9.6% 的患者失去了随访。两种治疗方案均显示出较高的完成率和疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open Forum Infectious Diseases Medicine-Neurology (clinical)

CiteScore

6.70

自引率

4.80%

发文量

630

审稿时长

9 weeks

期刊介绍： Open Forum Infectious Diseases provides a global forum for the publication of clinical, translational, and basic research findings in a fully open access, online journal environment. The journal reflects the broad diversity of the field of infectious diseases, and focuses on the intersection of biomedical science and clinical practice, with a particular emphasis on knowledge that holds the potential to improve patient care in populations around the world. Fully peer-reviewed, OFID supports the international community of infectious diseases experts by providing a venue for articles that further the understanding of all aspects of infectious diseases.